Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule designed to lengthen the DNA’s protective telomere caps, thereby promoting longevity in humans and canine animals by treating age-related conditions. TELOMIR-1 is undergoing studies to provide a therapeutic intervention against contracting a number of degenerative and age-related diseases. Its Telomir-1, is being investigated for its potential to address a range of conditions, including Type 2 diabetes, Wilson’s disease, progeria, Alzheimer’s disease, and cancer. The Company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life. It is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal.
Código da empresaTELO
Nome da EmpresaTelomir Pharmaceuticals Inc
Data de listagemFeb 09, 2024
CEOMr. Erez Aminov
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 09
Endereço900 West Platt Street, Suite 200
CidadeTAMPA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33606
Telefone18138642562
Sitehttps://telomirpharma.com/
Código da empresaTELO
Data de listagemFeb 09, 2024
CEOMr. Erez Aminov
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados